Disease spectrum of liver disease and its changing trend among inpatients in Nanjing Second Hospital from 2012 to 2021

Zhiyuan XU; Yongfeng YANG

doi:10.3969/j.issn.1001-5256.2023.09.016

Volume 39 Issue 9

Sep. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(9): 2137-2144

PDF( 901 KB)

Disease spectrum of liver disease and its changing trend among inpatients in Nanjing Second Hospital from 2012 to 2021

DOI: 10.3969/j.issn.1001-5256.2023.09.016

Zhiyuan XU¹,
Yongfeng YANG^{2
,
,
,}

1.
Nanjing Medical University School of Public Health，Nanjing 211166，China
2.
Department of Hepatology，Teaching Hospital，Nanjing Medical University School of Public Health （Nanjing Second Hospital），Nanjing 210003，China

Research funding:

Jiangsu Province Science and Education Rejuvenation Engineering Key Talent Project (ZDRCC2016013)

More Information

Corresponding author: YANG Yongfeng， yyf1997@163.com （ORCID： 0000－0002－0942－4833）
Received Date: 2022-12-02
Accepted Date: 2023-01-24
Published Date: 2023-09-19

Abstract

Abstract

Objective To investigate the etiology， type， and composition of liver diseases and the changing trend of the composition ratio of different liver diseases among inpatients in Nanjing Second Hospital in the recent ten years. Methods A total of 65 185 inpatients with the primary diagnosis of liver disease were collected in Nanjing Second Hospital from January 2012 to December 2021. Statistical analyses were performed based on the causes and types of liver disease in different years， and composition ratios were calculated. The chi－square test was used for comparison of composition ratio between groups. Results A total of 65 185 patients with liver disease were enrolled， among whom there were 43 110 male patients and 22 075 female patients. Comparison between years showed that as for the type of liver disease， the proportion of patients with liver injury decreased from 55.94% to 46.98% （χ²=282.894， P<0.001）. In terms of etiological distribution， viral hepatitis was still the main etiology， but its composition ratio decreased from 81.65% to 63.22% （χ²=433.919， P<0.001）， and the composition ratio of hepatitis B decreased from 87.09% to 71.96% （χ²=655.893， P<0.001）， while that of hepatitis C increased from 9.67% to 25.22% （χ²=858.840， P<0.001）. The composition ratio of non－viral liver diseases tended to increase， such as drug-induced liver injury， alcoholic liver disease， nonalcoholic fatty liver disease， and autoimmune liver disease. Among the main causes of end－stage liver disease， autoimmune liver disease showed an increasing trend from 2.01% to 11.77% （χ²=459.726， P<0.001）， which should be taken seriously by clinicians. Conclusion There are changes in the composition of main etiologies among inpatients with liver disease in Nanjing Second Hospital in the recent ten years， with the main etiology of viral hepatitis， but its composition ratio tends to decrease， while the composition ratio of non－viral liver disease is gradually increasing.
- Liver Diseases,
- Inpatients,
- Disease Spectrum

FullText(HTML)

References(22)

References

[1]	WANG FS, FAN JG, ZHANG Z, et al. The global burden of liver disease: the major impact of China[J]. Hepatology, 2014, 60( 6): 2099－ 2108. DOI: 10.1002/hep.27406.
[2]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 42－ 49. 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 42－ 49.
[3]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 35－ 41. 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 35－ 41.
[4]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary sclerosing cholangitis(2021)[J]. J Clin Hepatol, 2022, 38( 1): 50－ 61. 中华医学会肝病学分会. 原发性硬化性胆管炎诊断及治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38( 1): 50－ 61.
[5]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2648－ 2669. DOI: 10.3969/j.issn.1001－5256.2019.12.007.
[6]	Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C(2019 version)[J]. J Clin Hepatol, 2019, 35( 12): 2670－ 2686. DOI: 10.3969/j.issn.1001－5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 12): 2670－ 2686. DOI: 10.3969/j.issn.1001－5256.2019.12.008.
[7]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947－ 957. DOI: 10.3969/j.issn.1001－5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947－ 957. DOI: 10.3969/j.issn.1001－5256.2018.05.007.
[8]	Fatty Liver Expert Committee, Chinese Medical Doctor Association; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 939－ 946. DOI: 10.3969/j.issn.1001－5256.2018.05.006. 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 939－ 946. DOI: 10.3969/j.issn.1001－5256.2018.05.006.
[9]	Chinese Medical Association, Chinese Medical Journals Publishing House, Chinese Society of Gastroenterology, et al. Guidelines for the diagnosis and treatment of drug－induced liver injury(2019)[J]. Chin J Gen Pract, 2020, 19( 10): 868－ 875. DOI: 10.3760/cma.j.cn.114798－20200812－00900. 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 药物性肝损伤基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19( 10): 868－ 875. DOI: 10.3760/cma.j.cn.114798－20200812－00900.
[10]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35( 11): 2408－ 2425. DOI: 10.3969/j.issn.1001－5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35( 11): 2408－ 2425. DOI: 10.3969/j.issn.1001－5256.2019.11.006.
[11]	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007. 中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38－ 44. DOI: 10.3969/j.issn.1001－5256.2019.01.007.
[12]	LUO QM, CHEN J, LI ZP, et al. Recent advances in antiviral therapy for chronic hepatitis B[J]. Guangdong Med J, 2022, 43( 7): 843－ 848. DOI: 10.13820/j.cnki.gdyx.20222141. 罗秋敏, 陈佳, 李智鹏, 等. 慢性乙型肝炎抗病毒治疗新进展[J]. 广东医学, 2022, 43( 7): 843－ 848. DOI: 10.13820/j.cnki.gdyx.20222141.
[13]	SHAN S, JIA JD. Achievements in the prevention and control of chronic viral hepatitis B in the past decade[J]. Chin J Clin, 2022, 50( 10): 1131－ 1132. DOI: 10.3969/j.issn.2095－8552.2022.10.001. 单姗, 贾继东. 慢性乙型病毒性肝炎近十年防控成就[J]. 中国临床医生杂志, 2022, 50( 10): 1131－ 1132. DOI: 10.3969/j.issn.2095－8552.2022.10.001.
[14]	LANCASTER K, RHODES T, RANCE J. Towards eliminating viral hepatitis: Examining the productive capacity and constitutive effects of global policy on hepatitis C elimination[J]. Int J Drug Policy, 2020, 80: 102419. DOI: 10.1016/j.drugpo.2019.02.008.
[15]	ZHENG E, SANDHU N, NAVARRO V. Drug－induced liver injury secondary to herbal and dietary supplements[J]. Clin Liver Dis, 2020, 24( 1): 141－ 155. DOI: 10.1016/j.cld.2019.09.009.
[16]	SHEN T, LIU Y, SHANG J, et al. Incidence and etiology of drug－induced liver injury in mainland China[J]. Gastroenterology, 2019, 156( 8): 2230－ 2241. e 11. DOI: 10.1053/j.gastro.2019.02.002.
[17]	GREWAL P, AHMAD J. Severe liver injury due to herbal and dietary supplements and the role of liver transplantation[J]. World J Gastroenterol, 2019, 25( 46): 6704－ 6712. DOI: 10.3748/wjg.v25.i46.6704.
[18]	NAVARRO V, AVULA B, KHAN I, et al. The contents of herbal and dietary supplements implicated in liver injury in the united states are frequently mislabeled[J]. Hepatol Commun, 2019, 3( 6): 792－ 794. DOI: 10.1002/hep4.1346.
[19]	de ABAJO FJ, MONTERO D, MADURGA M, et al. Acute and clinically relevant drug－induced liver injury: a population based case－control study[J]. Br J Clin Pharmacol, 2004, 58( 1): 71－ 80. DOI: 10.1111/j.1365－2125.2004.02133.x.
[20]	VEGA M, VERMA M, BESWICK D, et al. The incidence of drug－ and herbal and dietary supplement－induced liver injury: preliminary findings from gastroenterologist－based surveillance in the population of the state of delaware[J]. Drug Saf, 2017, 40( 9): 783－ 787. DOI: 10.1007/s40264－017－0547－9.
[21]	SHEN Q, WANG XP, QIANG L. Research progress on the pathogenesis of drug－induced liver injury caused by different drugs[J]. J Pharm Res, 2022, 41( 9): 595－ 599. DOI: 10.13506/j.cnki.jpr.2022.09.007. 沈琴, 王晓萍, 强磊. 药物引起的肝损伤发病机制研究进展[J]. 药学研究, 2022, 41( 9): 595－ 599. DOI: 10.13506/j.cnki.jpr.2022.09.007.
[22]	Chinese Medical Association, Chinese Medical Association, Publishing House Gastroenterology Branch of Chinese Medical Association, et al. Guidelines for the primary diagnosis and treatment of alcoholic liver disease(2019)[J]. Chin J Gen Pract, 2020, 19( 11): 990－ 996. DOI: 10.3760/cma.j.cn114798－20200812－00898. 中华医学会, 中华医学会杂志社, 中华医学会消化病学分会, 等. 酒精性肝病基层诊疗指南(2019年)[J]. 中华全科医师杂志, 2020, 19( 11): 990－ 996. DOI: 10.3760/cma.j.cn114798－20200812－00898.

Relative Articles

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	陈红梅，苏健婷，佟超，王晶，刘庆萍，杜婧，王苹，韦再华. 2005—2020年北京市户籍居民病毒性肝炎死亡特征分析. 国际病毒学杂志. 2024(03): 233-237 .
2.	张燕云，蒋宗烨，雷淑娟，袁继丽，顾宏图，赵长青，慕永平，邢枫，刘成海. 并发细菌感染自身免疫性肝病肝硬化患者的临床特征与院内死亡风险因素分析. 中华传染病杂志. 2024(10): 618-625 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(6)

Get Citation

PDF

XML

Article Metrics

Article views (579) PDF downloads(45)

Disease spectrum of liver disease and its changing trend among inpatients in Nanjing Second Hospital from 2012 to 2021

DOI: 10.3969/j.issn.1001-5256.2023.09.016